기본 정보
- CAS
15826-37-6- 표준 SMILES
O=C([O-])c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)[O-])cc(=O)c34)cccc2o1.[Na+].[Na+]- InChIKey
VLARUOGDXDTHEH-UHFFFAOYSA-L- 분자식
- C23H14Na2O11
- 평균 분자량
- 512.3 g/mol
- 단동위원소 질량
- 512.03314982
개요
Disodium cromoglycate is an organic sodium salt that is the disodium salt of cromoglycic acid. It has a role as an anti-asthmatic drug and a drug allergen. It contains a cromoglycate(2-).
이름 및 식별자
- 우선 이름
- Disodium Cromoglycate
- IUPAC
- disodium;5-[3-(2-carboxylato-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylate
- 현지명
- 다이소듐크로몰린
- 영어명
- Cromolyn Disodium Salt
- 분자식
- C23H17NaO11
- 분자량
- 492.37
이름 및 동의어
CROMOLYN SODIUM15826-37-6Sodium cromoglycateDisodium cromoglycatesodium cromoglicateSodium cromolynGastrocromCromolyn disodium saltCromopticCrolomNatrii cromoglicasCromoglycate disodium
이름 더 보기
다이소듐크로몰린CromoglycatenatriumcromoglicatCromoglycate SodiumintalAllergocrom
Natrium cromoglicatCromoglicate SodiumLomusolRynacromAstilynDisodium cromolynDSCGDTXSID7044554
데이터베이스 식별자
- CAS
15826-37-6- PubChem CID
- 27503
- DTXSID
DTXSID7044554- ChEMBL
CHEMBL74- ChEBI
CHEBI:128458- UNII
- Q2WXR1I0PK
- EC Number
- 239-926-7
- Nikkaji
- J9.015H
물성
구조 계산 물성
- 극성 표면적
- 172 Ų
- 수소 결합 공여자 수
- 1
- 수소 결합 수용자 수
- 11
- 회전 가능 결합 수
- 6
- 무거운 원자 수
- 36
- 형식 전하
- 0
- 복잡도
- 824
실험 및 물리화학적 성질
Human Drugs
Breast Feeding; Lactation; Milk, Human; Anti-Allergic Agents; Anti-Asthmatic Agents
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Collision Cross Section205.6 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
물리화학적 성질
- 녹는점
- 241 · 241-2420C (dec)
- 저장 조건
- 2 · 2-8°C
- 용해도
- 물에 용해되고 에탄올에는 거의 용해되지 않습니다(96%).
- 물리적 상태
- Solid
- 색상
- 흰색에서 황백색까지
- 수용성
- 100 mg/ml까지 · 100mg/ml까지 물에 용해됨
- Merck
- 14 · 14,2590
- 안정성
- 흡습성
- 화장품 원료 기능
- 피지 억제
- InChIKey
- VLARUOGDXDTHEH-UHFFFAOYSA-L
- SMILES
- O(C1C=CC=C2OC(C(=O)O)=CC(=O)C=12)CC(O)COC1C=CC=C2OC(C(=O)O)=CC(=O)C=12.[NaH]
화학적 성질
White Crystalline Powder
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
GHS 분류
GHS Classification
This chemical does not meet GHS hazard criteria for 2% (2 of 98) of reports.
Warning
H315 (96.9%): Causes skin irritation [Warning Skin corrosion/irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 98 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
유해성 정보
Other Safety InformationIMAP assessments - 4H-1-Benzopyran-2-carboxylic acid, 5,5'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-, disodium salt: Environment tier I assessment
Hazard Classes and CategoriesSkin Irrit. 2 (96.9%)
독성 정보
Adverse Effects
The frequency of adverse events in patients using cromolyn sodium remains unclear. Adverse events also vary depending on the administration route. The ophthalmic solution is associated with transient eye burning upon administration, and eye dryness, puffiness, irritation, itchiness, rash, and styes may be seen. Adverse events reported with the cromolyn sodium nasal spray were nasal congestion, sneezing, nasal itching, nosebleeds, rhinoconjunctivitis, and headaches. Adverse events reported with the inhalation solution were throat irritation and hoarseness, esophagitis, laryngeal and pharyngeal edema, drowsiness, dizziness, bronchial irritation, pulmonary infiltrates, and cough.
Toxicity Summary
Cromolyn sodium is poorly absorbed and is low in toxicity. No severe toxicity reactions have been reported, and a specific toxic dose has not been established. Research verifying the efficacy or safety of cromolyn sodium is insufficient regarding use in pediatric patients younger than 2 years. However, acute life-threatening reactions have been reported.
화학 및 산업
약리 정보
FDA Pharmacological Classification
CROMOLYN SODIUM
Decreased Histamine Release [PE]; Mast Cell Stabilizer [EPC]
CROMOLYN SODIUM INHALATION SOLUTION
Mast Cell Stabilizer [EPC]; Decreased Histamine Release [PE]
CROMOLYN SODIUM ORAL SOLUTION (CONCENTRATE)
Decreased Histamine Release [PE]; Mast Cell Stabilizer [EPC]
MeSH Pharmacological Classification
Compounds that prevent the release of inflammatory mediators from MAST CELLS.
Drugs that are used to treat asthma.
응용 분야
용도Chromone complex which blocks mast cell degranulation
일반 설명Cromolyn sodium, disodium 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane (Intal), isa hygroscopic, white, hydrated crystalline powder that is solublein water (1:10). It is tasteless at first but leaves a veryslightly bitter aftertaste. The pK of cromolyn is 2. It is availableas a solution for a nebulizer, an aerosol spray, a nasal solution,an ophthalmic solution, and an oral concentrate.Nebulized and aerosol cromolyn has been used for prophylacticmanagement of bronchial asthma and prevention ofexercise-induced bronchospasm. Cromolyn nasal solution isused for the prevention and treatment of allergic rhinitis, andoral concentrate is used to treat the histaminic symptomsof mastocytosis (diarrhea, flushing, headaches, vomiting, urticaria,abdominal pain, nausea, and itching). Topical cromolyn(eye drops) is used to treat allergic conjunctivitis andkeratitis. In the treatment of asthma, cromolyn efficacy is manifestedby decreased severity of clinical symptoms, or need for concomitant therapy, or both. Long-term use is justified if thedrug significantly reduces the severity of asthma symptoms;permits a significant reduction in, or elimination of, steroiddosage; or improves management of those who have intolerableside effects to sympathomimetic agents or methylxanthines.For cromolyn to be effective, it must be administered atleast 30 minutes prior to antigen challenge and administered atregular intervals (see dosing information that follows). Wheninhaled, the powder does produce irritation in some patients.Also, overuse of cromolyn can result in tolerance.
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…